Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

TY - JOUR

T1 - Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

AU - Andorsky, David

AU - Coleman, Morton

AU - Yacoub, Abdulraheem

AU - Melear, Jason M.

AU - Brooks, Heather Dawn

AU - Fanning, Suzanne R.

AU - Kolibaba, Kathryn S.

AU - Lansigan, Frederick

AU - Reynolds, Chris

AU - Li, Jiahui

AU - Liu, Dongfang

AU - Llorente, Mary

AU - Ricker, Justin L.

AU - Sharman, Jeff Porter

N1 - 7516 Background: In the relapsed/refractory (R/R) setting for indolent non-Hodgkin lymphoma (iNHL), duration of response (DOR) to and types of prior therapy are important factors in predicting outcomes to subsequent therapy. Lenalidomide plus rituximab (R2) has shown promising efficacy and tolerability in multiple NHL studies.

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.7516

U2 - 10.1200/JCO.2018.36.15_SUPPL.7516

DO - 10.1200/JCO.2018.36.15_SUPPL.7516

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -